12:00 AM
 | 
Oct 14, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

LGD-6972: Phase I start

This quarter, Ligand will begin a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending-doses of oral LGD-6972...

Read the full 74 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >